UK markets open in 6 hours 11 minutes
  • NIKKEI 225

    -187.39 (-0.67%)

    -119.40 (-0.66%)

    +0.73 (+0.93%)

    +1.90 (+0.11%)
  • DOW

    +3.07 (+0.01%)

    +440.53 (+3.24%)
  • CMC Crypto 200

    +11.85 (+3.05%)
  • ^IXIC

    -65.72 (-0.59%)
  • ^FTAS

    +13.81 (+0.34%)

AlzeCure Presents at Bioscience 2022 on November 8

AlzeCure Pharma

STOCKHOLM, SWEDEN / ACCESSWIRE / November 3, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at the conference Bioscience 2022 - Bioscience Research and Diagnostics through innovative Technologies - where CEO Martin Jönsson will present Alzecure's R&D and their cooperation with academia.

The presentation, titled Developing pharmaceuticals against Alzheimer's and pain will be held in English by AlzeCure's CEO Martin Jönsson at 08:20 CET on November 8, 2022.

The conference will take place at Life City, Karolinska university hospital, Solnavägen 3H in Stockholm, Sweden.

For more information about the conference, program and registration, please see:

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative small molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets other types of severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable solutions for license agreements with other pharmaceutical companies.

FNCA Sweden AB is the company's Certified Adviser. For more information, please visit

Image Attachments

Martin Jönsson CEO AlzeCure Pharma


AlzeCure presents at Bioscience 2022 on November 8

SOURCE: AlzeCure Pharma

View source version on